Cabaletta Bio Analyst Ratings
UBS Initiates Cabaletta Bio(CABA.US) With Buy Rating, Announces Target Price $10
Stifel Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $26
HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $25 Price Target
H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $25
Evercore ISI Cuts Price Target on Cabaletta Bio to $15 From $25, Keeps Outperform Rating
Wells Fargo Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $20
Buy Rating Affirmed for Cabaletta Bio Amid Superior CD19 CAR T Therapy Efficacy in Autoimmune Disease Treatment
Cabaletta Bio Price Target Cut to $20.00/Share From $35.00 by Wells Fargo
Cabaletta Bio Analyst Ratings
Evercore ISI Group Maintains Outperform on Cabaletta Bio, Lowers Price Target to $15
Cabaletta Bio: Overweight Rating Maintained Amidst ICANS Incident and Adjusted Price Target
HC Wainwright & Co. Maintains Buy on Cabaletta Bio, Lowers Price Target to $25
Cabaletta Bio Analyst Ratings
Cabaletta Bio: A Buy Recommendation Despite Safety Incident, With Anticipated Future Growth in Autoimmune CAR-T
William Blair Sticks to Its Buy Rating for Cabaletta Bio (CABA)
Cantor Fitzgerald Reiterates Overweight on Cabaletta Bio, Maintains $50 Price Target
Cabaletta Bio Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $30 Price Target
Cabaletta Bio Analyst Ratings